

Matthieu Peyre

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1663011/publications.pdf>

Version: 2024-02-01

46
papers

1,248
citations

361413

20
h-index

395702

33
g-index

48
all docs

48
docs citations

48
times ranked

1382
citing authors

#	ARTICLE	IF	CITATIONS
1	Implementation of <i>TERT</i> promoter mutations improve prognostication of the WHO classification in meningioma. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	3.2	8
2	Clinical results after surgical resection of benign solitary schwannomas: A review of 150 cases. <i>Orthopaedics and Traumatology: Surgery and Research</i> , 2022, 108, 103281.	2.0	7
3	Associations of meningioma molecular subgroup and tumor recurrence. <i>Neuro-Oncology</i> , 2021, 23, 783-794.	1.2	83
4	Meningiomas from a developmental perspective: exploring the crossroads between meningeal embryology and tumorigenesis. <i>Acta Neurochirurgica</i> , 2021, 163, 57-66.	1.7	19
5	Current Management of Large Vestibular Schwannomas for <i>NF2</i> Patients in a National Reference Center. <i>Laryngoscope</i> , 2021, 131, E98-E107.	2.0	7
6	Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study. <i>Neuro-Oncology</i> , 2021, 23, 1139-1147.	1.2	10
7	Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort. <i>Journal of Neuro-Oncology</i> , 2021, 153, 55-64.	2.9	8
8	Sustained growth of intraosseous hormone-associated meningiomas after cessation of progestin therapy. <i>Acta Neurochirurgica</i> , 2021, 163, 1705-1710.	1.7	3
9	Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. <i>Neuro-Oncology</i> , 2021, 23, 1922-1935.	1.2	33
10	Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients. <i>Journal of Neurosurgery</i> , 2021, 134, 1377-1385.	1.6	11
11	GAB1 overexpression identifies hedgehog-activated anterior skull base meningiomas. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 748-755.	3.2	6
12	Mouse Models in Meningioma Research: A Systematic Review. <i>Cancers</i> , 2021, 13, 3712.	3.7	11
13	Somatic <i>PIK3CA</i> Mutations in Sporadic Cerebral Cavernous Malformations. <i>New England Journal of Medicine</i> , 2021, 385, 996-1004.	27.0	53
14	Primary Extraosseous Spinal Ewing Sarcomas. <i>Spine</i> , 2021, 46, 313-321.	2.0	2
15	Molecular alterations in meningioma: prognostic and therapeutic perspectives. <i>Current Opinion in Oncology</i> , 2020, 32, 613-622.	2.4	51
16	Natural history of peripheral nerve schwannomas. <i>Acta Neurochirurgica</i> , 2020, 162, 1883-1889.	1.7	3
17	Poor prognosis associated with <i>TERT</i> gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 378-387.	1.9	75
18	Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial. <i>Clinical Cancer Research</i> , 2020, 26, 552-557.	7.0	87

#	ARTICLE	IF	CITATIONS
19	Epineural glomus tumor of the posterior interosseous nerve: Case report. <i>Journal of Clinical Neuroscience</i> , 2020, 74, 232-234.	1.5	5
20	Response to: "what is the advantage of using sodium fluorescein during resection of peripheral nerve tumors?" <i>Acta Neurochirurgica</i> , 2020, 162, 1157-1157.	1.7	1
21	Prognostic Value of Histopathological Features and Loss of H3K27me3 Immunolabeling in Anaplastic Meningioma: A Multicenter Retrospective Study. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 754-762.	1.7	39
22	Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. <i>Journal of Neurosurgery</i> , 2020, 133, 1345-1354.	1.6	83
23	An Overview of Meningiomas. , 2020, , 3-10.		1
24	Extracapsular dissection in peripheral nerve schwannoma surgery using bright light and fluorescein sodium visualization: case series. <i>Acta Neurochirurgica</i> , 2019, 161, 2447-2452.	1.7	7
25	Treatment of grade II intracranial meningioma with helical tomotherapy. <i>Journal of Clinical Neuroscience</i> , 2019, 59, 190-196.	1.5	3
26	Current treatment options for meningioma. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 241-249.	2.8	147
27	De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors. <i>Neuro-Oncology</i> , 2018, 20, 1113-1121.	1.2	56
28	Management of meningioma. <i>Presse Medicale</i> , 2018, 47, e245-e252.	1.9	29
29	Selective vulnerability of the primitive meningeal layer to prenatal Smo activation for skull base meningothelial meningioma formation. <i>Oncogene</i> , 2018, 37, 4955-4963.	5.9	29
30	<i>SMO</i> mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas. <i>Neuro-Oncology</i> , 2017, 19, now276.	1.2	49
31	Cytoplasmic overexpression of RNA-binding protein HuR is a marker of poor prognosis in meningioma, and HuR knockdown decreases meningioma cell growth and resistance to hypoxia. <i>Journal of Pathology</i> , 2017, 242, 421-434.	4.5	27
32	Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas. <i>Journal of Neuro-Oncology</i> , 2017, 133, 633-639.	2.9	4
33	Dramatic Shrinkage with Reduced Vascularization of Large Meningiomas After Cessation of Progestin Treatment. <i>World Neurosurgery</i> , 2017, 101, 814.e7-814.e10.	1.3	23
34	Internal Auditory Canal Decompression for Hearing Maintenance in Neurofibromatosis Type 2 Patients. <i>Neurosurgery</i> , 2016, 79, 370-377.	1.1	14
35	Grade II meningiomas and Gamma Knife radiosurgery: analysis of success and failure to improve treatment paradigm. <i>Journal of Neurosurgery</i> , 2016, 125, 89-96.	1.6	31
36	Endothelial Cell Hypertrophy and Microvascular Proliferation in Meningiomas Are Correlated with Higher Histological Grade and Shorter Progression-Free Survival. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 1160-1170.	1.7	16

#	ARTICLE	IF	CITATIONS
37	PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with <i>Nf2</i> and <i>Cdkn2ab</i> loss. <i>Oncotarget</i> , 2015, 6, 32713-32722.	1.8	35
38	Patterns of relapse and growth kinetics of surgery- and radiation-refractory meningiomas. <i>Journal of Neuro-Oncology</i> , 2015, 123, 151-160.	2.9	8
39	Multiple meningiomas in patients with Turner syndrome. <i>Acta Neurochirurgica</i> , 2015, 157, 621-623.	1.7	6
40	Miniaturized Handheld Confocal Microscopy Identifies Focal Brain Invasion in a Mouse Model of Aggressive Meningioma. <i>Brain Pathology</i> , 2013, 23, 371-377.	4.1	20
41	Conservative Management of Bilateral Vestibular Schwannomas in Neurofibromatosis Type 2 Patients. <i>Neurosurgery</i> , 2013, 72, 907-914.	1.1	38
42	New insights into meningioma. <i>Current Opinion in Oncology</i> , 2012, 24, 660-665.	2.4	22
43	Multifocal choroid plexus papillomas: case report. <i>Acta Neurochirurgica</i> , 2012, 154, 295-299.	1.7	11
44	Posterior petrous bone meningiomas: surgical experience in 53 patients and literature review. <i>Neurosurgical Review</i> , 2012, 35, 53-66.	2.4	21
45	Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2. <i>Neuro-Oncology</i> , 2011, 13, 1125-1132.	1.2	19
46	Meningioma mouse models. <i>Journal of Neuro-Oncology</i> , 2010, 99, 325-331.	2.9	23